Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Inhibitor Therapeutics, Inc. INTI

14 fiscal years on record · USD · FY2025 reported · SEC filings only
$-3.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 14-year series below
Revenue $M Net income $M
FY2021 · Revenue 0.0 · Net income -0.3
-2.5M-5.0M
201220152018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2024 · ROE -91.9%
-2000%-4000%
201220182025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -102%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Net buybacks $ Dividends $
FY2020 · Dividends 0.0 · Net buybacks ·
4000080000
20192020

Total assetsUSD 2.5M
EquityUSD -1.3M
CashUSD 2.4M
Gross debtUSD 36,889.00
Net debtUSD -2.3M
Current ratio3.19×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 14-year record

14 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
INTI, 14-year financial record
Metric 20252024202320222021202020192018201720162015201420132012
Revenue $B◌◌◌◌0.00.00.00.00.00.00.00.00.0◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B◌◌◌◌◌◌◌◌◌◌◌◌−0.0−0.0
Income tax $B◌◌◌0.00.00.00.00.00.00.00.00.00.0◌
Net income $B−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0
EPS, diluted $−0.02−0.02−0.020.030.000.00−0.01−0.01−0.01−0.02−0.02−0.04−0.100.01
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %—————−0−4———————
ROE %—−91.9−44.6————−4575.1−141.8−187.8−1625.1———
Shares out B0.170.170.170.170.380.370.370.370.370.350.250.210.020.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 54 reconciliationsAUDITED

Reconciled in 14 of the 14 fiscal years we could check. 10 checks were skipped: the balance sheet is not tagged before 2012. Five checks were skipped: EPS is not tagged before 2012.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2012

Share this section

Download image